GlassScriptPhysician profile
Mark Slootsky
NPI 1396124749
$2,055.14
in general payments reported to CMS, 2019-2025
20 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $424 · 2023: $363 · 2024: $625 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,631.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.66 | 2022-2024 | Ofev |
| Inspire Medical Systems, INC. | $259.64 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $251.05 | 2022-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $180.00 | 2024-2025 | Fasenra, Airsupra, Tezspire |
| Inari Medical, INC. | $173.34 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Coaptech, INC. | $147.64 | 2023 | Puma System |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2022 | |
| Merck Sharp & Dohme LLC | $124.45 | 2025 | Winrevair |
| Verona Pharma, INC. | $105.69 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $87.64 | 2024-2025 | Glassia, Cuvitru |
| Actelion Pharmaceuticals US, INC. | $37.16 | 2024 | Uptravi, Opsumit |
| Baxter Healthcare | $31.42 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $28.99 | 2024 | |
| Abbvie INC. | $25.68 | 2025 | |
| Amgen INC. | $25.40 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23.56 | 2024 | Terlivaz |
| Vifor Pharma, INC. | $22.17 | 2025 | Zemaira |
| Pulmonx Corporation | $19.31 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Lilly USA, LLC | $16.78 | 2025 | Mounjaro, Zepbound |
| Electromed, INC. | $15.56 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Slootsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.